The largest database of trusted experimental protocols

52 protocols using elecsys system

1

Diagnostic Criteria for Hypocalcemia

Check if the same lab product or an alternative is used in the 5 most similar protocols
The symptoms and signs of symptomatic hypocalcemia include numbness or tingling around the mouth and fingers, muscle spasms, or cramps in the limbs. Other signs include the Chvostek sign and Trousseau sign. PTH was measured using an electrochemiluminescence immunoassay (Roche Elecsys System, Roche Diagnostics, Mannheim, Germany), and serum calcium was measured by the o-cresolphthalein complexone method (reference values 15–65 pg/mL and 2.0–2.6 mmol/L, respectively, according to the manufacturer’s normative data). Hypoparathyroidism was defined as PTH level below the normal range. PTH < 15 pg/mL has been adopted by some studies [6 (link), 12 (link), 13 (link)]. Normal parathyroid function was defined as PTH > 15 pg/mL without oral calcium or calcitriol replacement therapy. Permanent hypoparathyroidism was defined as postoperative PTH < 15 pg/mL lasting for more than 1 year and requiring oral calcium or calcitriol replacement therapy. The serum magnesium concentration reference value ranges from 0.66 to 1.07 mmol/L, and the serum phosphorus concentration value reference ranges from 0.86 to 1.78 mmol/L.
+ Open protocol
+ Expand
2

Standardized CSF Biomarker Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
CSF was obtained using a harmonized pre‐analytical protocol. Analyses were performed using the fully automatized Roche Elecsys System in a single laboratory (University of Gothenburg).17 Concentrations of Aβ1‐42, phosphorylated tau (p‐tau181), and total tau (t‐tau) were determined according to the manufacturer's instructions.
+ Open protocol
+ Expand
3

Cerebrospinal Fluid Biomarker Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the entire cohort, Aβ and total tau concentrations were measured using β-amyloid (1–42) and hTau Ag ELISA tests. Aβ42 and total tau levels were measured on the Roche Elecsys system. These measurements were performed by Clinical Laboratory Improvement Amendments (CLIA)-certified Mayo Clinic Laboratories following manufacturers’ instructions. CSF Aβ42 and total tau cut-offs follow Mayo Clinic reference values: Aβ42 at 1026 pg/ml and total tau cut-off at 238 pg/ml (Hansson et al., 2018 (link)).
+ Open protocol
+ Expand
4

Biomarkers Assessing Iron Status

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following blood biomarkers reflecting iron status were measured at study entry: Serum iron (ug/dL) was measured using spectrophotometry, serum ferritin (ng/mL) and transferrin (mg/dL) were measured using immunoturbidimetry. Transferrin saturation index (TSAT) was estimated using the formula: TSAT = serum iron (ug/dL)/[serum transferrin (mg/dL) × 1.25] [13 ]. ID was defined as absolute when ferritin < 100 ng/ml and functional when TSAT < 20% with ferritin 100–299 ng/ml [8 (link)].
Haemoglobin was measured using impedance laser colorimetry and anaemia was defined as Haemoglobin < 12 g/dL in women and Haemoglobin < 13 g/dL in men. Concentrations of N-terminal pro-brain-type natriuretic peptide (NT-proBNP) were measured using an immunoassay based on electrochemiluminescence on the Elecsys System (Roche Diagnostics, Basel, Switzerland). Renal function was assessed with the estimated glomerular filtration rate using the abbreviated Modification of Diet in Renal Disease equation.
+ Open protocol
+ Expand
5

Bone Turnover Markers in ROMO Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood samples were collected in the morning following an overnight fast. Bone turnover markers were measured at baseline and subsequently at 1, 6, and 12 months during the ROMO treatment. Total N-terminal type I procollagen propeptide (PINP; interassay coefficient of variation ≤ 5.0%; Roche Diagnostics, Basel, Switzerland) served as a bone formation marker, and Isoform 5b of tartrate-resistant acid phosphatase (TRACP-5b; interassay coefficient of variation ≤ 9.0%; Nittobo Medical Co. Ltd., Tokyo, Japan) was measured as a bone resorption marker (TRACP-5b demonstrates superior sensitivity and signal-to-noise ratio compared to serum cross-linked C-telopeptide of type I collagen (CTX) [13 (link)]). Serum 25-hydroxycholecalciferol (25(OH)D) levels were assessed via electrochemiluminescence using the Elecsys system (Roche Diagnostics, Basel, Switzerland).
+ Open protocol
+ Expand
6

Determining tHcy, Vitamin B6, Folate, and B12

Check if the same lab product or an alternative is used in the 5 most similar protocols
tHcy and vitamin B6 (as pyridoxal-5-phosphate) concentration were determined by HPLC using a commercially available kit (Chromsystems Instruments & Chemicals GmbH, Munich, Germany) and fluorescent detection, where a derivatization process of the sample takes place. Once the sample is prepared, 50 µL are injected into the HPLC and fluorescence is measured at 385 nm excitation and 515 nm emission for tHcy and 320 nm excitation and 415 nm emission for vitamin B6.
Folate and vitamin B12 concentrations were measured using an ELECSYS system (Roche Diagnostics GmbH, Mannheim, Germany) based on an electrochemiluminescence immunoassay (ECLIA).
+ Open protocol
+ Expand
7

Quantitative HBV-DNA and Serum Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols
HBV-DNA levels were quantitated by real-time quantitative PCR using the ABI7300 thermocycler (AppliedBiosystems, Foster City, CA, USA). The limit of detection of the assay was 500 copies/mL. Serum HBV markers, including hepatitis B s antigen (HBsAg), hepatitis B s antibody (HBsAb), hepatitis B e antigen (HBeAg), hepatitis B e antibody (HBeAb), and hepatitis B c antibody (HBcAb), were determined using the Elecsys system (Hoffmann-La Roche, Basel, Switzerland).
+ Open protocol
+ Expand
8

Assessing Liver Disease Severity

Check if the same lab product or an alternative is used in the 5 most similar protocols
The MELD-Na score was used to assess disease severity and calculated as previously described [18 (link)]. If the sodium values were below 125 mmol/L, they were set to 125 mmol/L, and if the values were above 140 mmol/L, they were adjusted to 140 mmol/L. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (Tbil), albumin (ALB), globulin (GLB), and creatinine (Cr) were quantitated using an autoanalyzer (TBA-30FR Toshiba, Tokyo, Japan). Prothrombin time (PT) and prothrombin time activity (PTA) were measured using an automatic hemostasis/thrombosis analyzer (STA compact, Holliston, MA, USA). Alpha-fetoprotein (AFP) was determined using Roche's Elecsys system (Hoffmann-La Roche, Basel, Switzerland).
+ Open protocol
+ Expand
9

Quantitative Evaluation of Liver Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols
The levels of serum HBV markers (including HBsAg, HBeAg, HBeAb, and HBcAb) and AFP were measured using an Elecsys system (Hoffman-La Roche Ltd., Basel, Switzerland). HBV-DNA levels were quantitated with RT-PCR using an ABI7300 instrument (Thermo Fisher Scientific). The detection limit of HBV-DNA was 100 IU/mL. Biochemical assays were performed using an autoanalyzer (TBA-30FR; Toshiba, Tokyo, Japan). PTA was measured using an automatic hemostasis/thrombosis analyzer (STA Compact, Holliston, MA, USA).
+ Open protocol
+ Expand
10

Investigating Alzheimer's Biomarkers through Multimodal Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
Eventually, we explored the sanity and relevance of IDPs by assessing their relationship to non-imaging data whose association with brain phenotypes has been established in the Alzheimer literature. Specifically, the association of each computed IDP with age was assessed through the Pearson correlation coefficient, while relationship with amyloid status (CSF amyloid positivity), cognitive status (CDR score) and APOE e-4 carriership was evaluated using T tests. Amyloid positivity was defined with CSF Aβ1-42 levels < 1000 pg/mL (fully automated Roche cobas Elecsys System), following previous works on the same cohort (Ingala et al., 2021 ). IDPs used for this analysis included global WMH volume, GM volume in 10 regions which have shown to involved in the early stages of Alzheimer’s Disease (Marizzoni et al., 2019 (link)), mean functional connectivity in canonical RSN from the low dimensional ICA, global and regional FA values (for 9 regions of interest), and global CBF values. We did not explore the effect of covariate correction or multiple testing on these correlations.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!